Larkspur Health Acquisition Corp - Warrants (20/12/2026

(Warrants)
NEW
NAS:LSPRW (USA)   Warrants (20/12/2026)
$ 0.18 (0%) 09:42 AM EST
At Loss
P/B:
3.03
Market Cap:
$ 0
Enterprise V:
$ 0
Volume:
0
Avg Vol (2M):
0
Warning! GuruFocus detected 1 Medium warning sign with LSPRW. Try a 7-Day Free Trial to check it out.
Volume:
0
Market Cap $:
0
At Loss
Avg Vol (2M):
0
Enterprise Value $:
0
PB Ratio:
3.03
What is a stock summary page? Click here for an overview. Powered by GuruAPI
SEC Filings Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocksâ„¢

Business Description

Larkspur Health Acquisition Corp
NAICS : 551112 SIC : 6719
100 Somerset Corporate Boulevard, 2nd Floor, Bridgewater, NJ, USA

Share Class Description:

LSPRW: Warrants (20/12/2026)
Compare
Compare
CLAYWTMAKACLFGMCWBQNLVHAQRDBXVBOCSCVXBHSEGSHNPSTHXAMS:EPICASZCCYCCVIIKAHCDWACIPOFPBAJ
Traded in other countries / regions
IPO Date
2022-02-10
Description
Larkspur Health Acquisition Corp is a blank check company.

Financial Strength

9/10
Name Current Vs Industry Vs History
Cash-To-Debt
 No Debt
Equity-to-Asset
 0.94
Interest Coverage
 No Debt
Piotroski F-Score
 N/A/9
0
1
2
3
4
5
6
7
8
9

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
 0.27
Quick Ratio
 0.27
Cash Ratio
 0.13

Dividend & Buy Back

Name Current Vs Industry Vs History

Profitability Rank

1/10
Name Current Vs Industry Vs History
ROE %
 -3.4
ROA %
 -3.21
ROIC %
 -4.12
ROCE %
 -4.04

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio
 3.03
EV-to-EBIT
 -89.6
EV-to-EBITDA
 -89.6
EV-to-FCF
 -316.09
Earnings Yield (Greenblatt) %
 -1.12
FCF Yield %
 -0.32

GF Valueâ„¢

LSPRW

Larkspur Health Acquisition Corp Filings

Filing Date Document Date Form
No Filing Data

Larkspur Health Acquisition Corp Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Guru Commentaries on NAS:LSPRW

No articles.

Press Release

Subject Date
ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA") 2022-12-12
ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit 2022-11-22
SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc. 2022-11-15
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference 2022-10-28
Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC Inhibitor, IC 100, Is Effective in Reducing Brain Inflammation in a Preclinical Model of Aging 2022-08-22
Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4 Regarding the Proposed Business Combination with ZyVersa Therapeutics 2022-08-15
ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper 2022-08-03
Larkspur Health Acquisition Corp. Announces Class A Common Stock and Warrants to Commence Trading Separately on February 10, 2022 2022-02-08
Larkspur Health Acquisition Corp. Announces Closing of $75 Million Initial Public Offering 2021-12-23
10/Page
  • 1

Articles on Larkspur Health Acquisition Corp

No articles.

Headlines

See More
  • 1
No news.
  • 1
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文
Education
Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2026 GuruFocus.com, LLC. All Rights Reserved.